Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,761.00up ₹3.50 (0.20%)BSE ₹1,762.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,757.50.
29 Oct: open ₹1,757.50, high ₹1,771.50, low ₹1,752.70
52-week range of traded prices to 29 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,22,523 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.93
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.06
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.91%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,07,85459.5% delivered
Sun Pharmaceutical Industries has 1,448 announcements on record, routine notices left out; 12 in the 30 days to 29 Oct 2026, the latest on 26 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Sun Pharmaceutical Industries quarterly results
Oct30Fri
The board meets on 30 Oct 2026 to consider financial results
Notice filed 14 Oct 2026
Sun Pharmaceutical Industries annual reports, presentations and earnings calls
The company's own documents, latest first.Sun Pharmaceutical Industries financials, year by year
Annual reports17
- Annual report, year to Mar 20266 Jul 2026
- Annual report, year to Mar 20254 Jul 2025
- Annual report, year to Mar 20248 Jul 2024
- Annual report, year to Mar 202327 Jul 2023, a zip file
- Annual report, year to Mar 20225 Aug 2022, a zip file
12 earlier reports
- Annual report, year to Mar 20216 Aug 2021, a zip file
- Annual report, year to Mar 20203 Aug 2020, a zip file
- Annual report, year to Mar 201930 Jul 2019, a zip file
- Annual report, year to Mar 20181 Oct 2018, a zip file
- Annual report, year to Mar 201729 Sep 2017, a zip file
- Annual report, year to Mar 201623 Sep 2016, a zip file
- Annual report, year to Mar 20156 Oct 2015, a zip file
- Annual report, year to Mar 201416 Sep 2014, a zip file
- Annual report, year to Mar 201217 Oct 2013, a zip file
- Annual report, year to Mar 201317 Sep 2013, a zip file
- Annual report, year to Mar 201120 Sep 2011, a zip file
- Annual report, year to Mar 201013 Apr 2011, a zip file
Investor presentations19
- Investor Presentation22 Sep 2026
- Investor Presentation7 Jul 2026
- Investor Presentation27 Apr 2026
- Investor Presentation24 Feb 2026
- Investor Presentation26 Dec 2025
14 earlier presentations
- Investor Presentation1 Sep 2025
- Investor Presentation14 Jul 2025
- Investor Presentation4 Mar 2025
- Investor Presentation28 Nov 2024
- Investor Presentation30 Sep 2024
- Investor Presentation10 Jul 2024
- Investor Presentation14 Mar 2024
- Investor Presentation4 Jan 2024
- Investor Presentation11 Sep 2023
- Investor Presentation21 Jul 2023
- Investor Presentation28 Apr 2023
- Investor Presentation16 Jan 2023
- Investor Presentation16 Sep 2022
- Investor Presentation related to the merger of Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd.7 Apr 2014, a zip file
Earnings calls40
- Transcript6 Aug 2026
- Link of Recording31 Jul 2026
- Transcript29 May 2026
- Link of Recording22 May 2026
- Transcript5 May 2026
35 earlier call documents
- Link of Recording27 Apr 2026
- Transcript4 Feb 2026
- Link of Recording31 Jan 2026
- Transcript11 Nov 2025
- Link of Recording5 Nov 2025
- Transcript6 Aug 2025
- Link of Recording31 Jul 2025
- Transcript29 May 2025
- Link of Recording22 May 2025
- Transcript6 Feb 2025
- Link of Recording31 Jan 2025
- Q2 FY25 Earnings Call Transcript4 Nov 2024
- Link of Recording28 Oct 2024
- Transcript7 Aug 2024
- Link of Recording1 Aug 2024
- Transcript29 May 2024
- Link of Recording22 May 2024
- Transcript6 Feb 2024
- Link of Recording31 Jan 2024
- Transcript8 Nov 2023
- Link of Recording1 Nov 2023
- Transcript9 Aug 2023
- Link of Recording3 Aug 2023
- Transcript31 May 2023
- Link of Recording26 May 2023
- Transcript1 Feb 2023
- Link of Recording1 Feb 2023
- Transcript of Analysts/Institutional Investor Meet/Con. Call5 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call1 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call3 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call29 Jul 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call2 Jun 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call30 May 2022
- Transcript3 Feb 2022
- Transcript11 Nov 2021
Sun Pharmaceutical Industries merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings13
- Effective date of Composite Scheme of Arrangement22 Nov 2025
- Approval of Composite Scheme of Arrangement by NCLT8 Oct 2025
- Amalgamation/Merger30 May 2022
- Scheme of Arrangement sanctioned by Hon'ble National Company Law Tribunal16 Sep 2021
- Approval of Scheme of Amalgamation and Merger of Sun Pharma Global FZE, an indirect wholly owned subsidiary of the Company, into the Company by the Board of Directors at its meeting held on July 31, 202031 Jul 2020
8 earlier filings
- NCLT Order on Scheme of Arrangement27 Dec 2019
- Scheme of Arrangement among Sun Pharma Global FZE and Sun Pharmaceutical Industries Limited ("the Company") and their respective members and creditors3 Dec 2018
- Board of Directors of the Company at its Meeting held on May 25, 2018 - Approved the Composite Scheme of Arrangement among Sun Pharmaceutical Industries Limited ( Transferor Company) and Sun Pharma (Netherlands) B.V. ( Transferee Company 1) and Sun Pharmaceutical Holdings USA Inc. ( Transferee Company 2) and their respective members and creditors25 May 2018, a zip file
- Scheme of Arrangement approved at Board Meeting held on November 14, 2017.14 Nov 2017, a zip file
- Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and Sun Pharmaceutical Industries Limited and their respective members and creditors and filing of E-form INC-28 with Registrar of Companies8 Sep 2017, a zip file
- Approval of Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited and the Company and their respective members and creditors14 Aug 2017, a zip file
- Hon'ble High Court of Punjab & Haryana has on March 9, 2015 orally pronounced an Order, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories Ltd. with the Company,Sun Pharmaceutical Industries Ltd. under Sections 391 to 394, Sections 78 and 100 of the Companies Act, 1956 and Section 52 of the Companies Act, 2013.9 Mar 2015, a zip file
- Vide letter dated November 24, 2014 regarding the Approval of Scheme of Arrangement between Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Ltd in the nature of merger of Ranbaxy Laboratories Limited with the Company.24 Nov 2014, a zip file
Sun Pharmaceutical Industries share news and announcements
Newest first. Page 1 of 29.
Oct 2026
23 Oct · Business
20 Oct · Business
15 Oct · Analysts
13 Oct · Rating
12 Oct · Management
12 Oct · Board meeting
1 Oct · Meeting
Sep 2026
29 Sep · Updates
28 Sep · Updates
28 Sep · Business
26 Sep · General Updates
11 Sep · General Updates
9 Sep · General Updates
8 Sep · Rating
3 Sep · Analysts
Aug 2026
25 Aug · Meeting
25 Aug · Analysts
17 Aug · General Updates
5 Aug · Analysts
5 Aug · Rating
Jul 2026
31 Jul · General Updates
31 Jul · Meeting
31 Jul · General Updates
27 Jul · General Updates
14 Jul · Analysts
Jun 2026
20 Jun · General Updates
14 Jun · General Updates
May 2026
27 May · Analysts
26 May · General Updates
25 May · Analysts
22 May · General Updates
22 May · General Updates
14 May · General Updates
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 14 Oct 2026Credit ratingdown 1.37%−1.1 pts vs Nifty 500market median 0.0% · five sessions −1.4% (−0.3 pts vs Nifty 500) · volume 1.1× usual · delivery +4.4 pts against usual · The announcement
- 13 Oct 2026Board or managers changedup 0.61%−0.6 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−2.0 pts vs Nifty 500) · volume 0.7× usual · delivery −3.4 pts against usual · The announcement
- 9 Sep 2026Credit ratingdown 1.11%−0.5 pts vs Nifty 500market median 0.0% · five sessions −1.7% (+0.8 pts vs Nifty 500) · volume 0.9× usual · delivery −2.2 pts against usual · The announcement
- 5 Aug 2026Credit ratingdown 1.22%−1.4 pts vs Nifty 500market median 0.0% · five sessions −1.1% (−1.1 pts vs Nifty 500) · volume 0.8× usual · delivery +3.9 pts against usual · The announcement
- 31 Jul 2026Resultsdown 0.53%−1.0 pts vs Nifty 500market median −0.7% · five sessions −2.5% (−4.1 pts vs Nifty 500) · volume 2.1× usual · delivery −9.9 pts against usual · The announcement
- 22 May 2026Resultsdown 2.47%−2.7 pts vs Nifty 500market median −0.7% · five sessions −4.9% (−5.1 pts vs Nifty 500) · volume 0.7× usual · delivery −15.2 pts against usual · The announcement
- 8 May 2026Credit ratingup 0.74%+1.2 pts vs Nifty 500market median 0.0% · five sessions +1.6% (+4.2 pts vs Nifty 500) · volume 0.5× usual · delivery +3.8 pts against usual · The announcement
- 1 Feb 2026Resultsup 0.93%+3.0 pts vs Nifty 500market median −0.7% · five sessions +6.7% (+5.3 pts vs Nifty 500) · volume 0.9× usual · delivery −40.4 pts against usual · The announcement
- 6 Nov 2025Resultsdown 0.24%+0.4 pts vs Nifty 500market median −0.7% · five sessions +2.5% (+1.8 pts vs Nifty 500) · volume 1.9× usual · delivery −12.6 pts against usual · The announcement
- 31 Jul 2025Resultsdown 1.56%−1.0 pts vs Nifty 500market median −0.7% · five sessions −8.0% (−6.4 pts vs Nifty 500) · volume 1.9× usual · delivery −21.8 pts against usual · The announcement
20 earlier announcements
- 23 May 2025Resultsdown 2.04%−2.9 pts vs Nifty 500market median −0.7% · five sessions −1.1% (−2.3 pts vs Nifty 500) · volume 2.9× usual · delivery +5.1 pts against usual · The announcement
- 7 May 2025Board or managers changeddown 2.08%−2.6 pts vs Nifty 500market median 0.0% · five sessions −6.5% (−8.3 pts vs Nifty 500) · volume 0.7× usual · delivery −0.3 pts against usual · The announcement
- 31 Jan 2025Dividendup 0.28%−1.1 pts vs Nifty 500market median 0.0% · five sessions +0.8% (−1.5 pts vs Nifty 500) · volume 2.4× usual · delivery −5.1 pts against usual · The announcement
- 23 May 2024Dividenddown 2.87%−4.1 pts vs Nifty 500market median 0.0% · five sessions −3.9% (−4.0 pts vs Nifty 500) · volume 5.7× usual · delivery +3.7 pts against usual · The announcement
- 4 Apr 2024Board or managers changeddown 0.03%−0.3 pts vs Nifty 500market median 0.0% · five sessions −1.0% (−2.5 pts vs Nifty 500) · volume 0.9× usual · delivery −30.4 pts against usual · The announcement
- 31 Jan 2024Dividendup 3.40%+2.2 pts vs Nifty 500market median 0.0% · five sessions +7.5% (+5.2 pts vs Nifty 500) · volume 2.8× usual · delivery −14.6 pts against usual · The announcement
- 8 Dec 2023Board or managers changeddown 0.28%−0.3 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−2.1 pts vs Nifty 500) · volume 1.1× usual · delivery +2.5 pts against usual · The announcement
- 1 Nov 2023Resultsup 2.54%+2.9 pts vs Nifty 500market median −0.7% · five sessions +7.6% (+5.3 pts vs Nifty 500) · volume 2.3× usual · delivery −5.5 pts against usual · The announcement
- 26 May 2023Dividendup 2.63%+1.7 pts vs Nifty 500market median 0.0% · five sessions +4.5% (+3.2 pts vs Nifty 500) · volume 1.7× usual · delivery −26.5 pts against usual · The announcement
- 17 Jan 2023Dividenddown 0.27%−0.9 pts vs Nifty 500market median 0.0% · five sessions +1.3% (+0.7 pts vs Nifty 500) · volume 0.6× usual · delivery +4.0 pts against usual · The announcement
- 1 Nov 2022Resultsup 1.94%+1.2 pts vs Nifty 500market median −0.7% · five sessions +1.1% (−0.1 pts vs Nifty 500) · volume 1.9× usual · delivery −25.6 pts against usual · The announcement
- 29 Jul 2022Resultsup 5.40%+4.0 pts vs Nifty 500market median −0.7% · five sessions +2.6% (−0.3 pts vs Nifty 500) · volume 4.6× usual · delivery −26.7 pts against usual · The announcement
- 31 May 2022Dividenddown 3.12%−2.9 pts vs Nifty 500market median 0.0% · five sessions −3.2% (−2.5 pts vs Nifty 500) · volume 7.6× usual · delivery +6.1 pts against usual · The announcement
- 25 Jan 2022Dividendup 0.90%+0.1 pts vs Nifty 500market median 0.0% · five sessions +11.4% (+8.6 pts vs Nifty 500) · volume 1.0× usual · delivery +5.5 pts against usual · The announcement
- 2 Nov 2021Resultsup 0.44%+0.4 pts vs Nifty 500market median −0.7% · five sessions −1.3% (−2.9 pts vs Nifty 500) · volume 6.4× usual · delivery −23.1 pts against usual · The announcement
- 28 May 2021Dividenddown 4.25%−4.6 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−5.8 pts vs Nifty 500) · volume 3.5× usual · delivery +26.2 pts against usual · The announcement
- 29 Jan 2021Dividendup 3.87%+5.1 pts vs Nifty 500market median 0.0% · five sessions +11.9% (+4.5 pts vs Nifty 500) · volume 3.0× usual · delivery −5.9 pts against usual · The announcement
- 21 Jan 2021Dividenddown 1.98%−1.5 pts vs Nifty 500market median 0.0% · five sessions −5.1% (+0.2 pts vs Nifty 500) · volume 0.6× usual · delivery −2.2 pts against usual · The announcement
- 28 Sep 2020Buybackup 4.18%+2.3 pts vs Nifty 500market median 0.0% · five sessions +6.8% (+2.9 pts vs Nifty 500) · volume 1.1× usual · delivery −5.1 pts against usual · The announcement
- 27 May 2020Dividenddown 1.80%−4.1 pts vs Nifty 500market median 0.0% · five sessions +3.0% (−6.6 pts vs Nifty 500) · volume 1.2× usual · delivery −7.5 pts against usual · The announcement
Sun Pharmaceutical Industries results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Revenue from operations | Quarter to Jun 2025 | Standalone | 5,601.96 | 5,594.88 | −0.1% | 31 Jul 2025 | 5 Nov 2025 |
| Total income | Quarter to Jun 2025 | Standalone | 5,705.65 | 5,698.59 | −0.1% | 31 Jul 2025 | 5 Nov 2025 |
| Materials used | Quarter to Jun 2025 | Standalone | 1,067.24 | 997.93 | −6.5% | 31 Jul 2025 | 5 Nov 2025 |
| Employee costs | Quarter to Jun 2025 | Standalone | 715.00 | 738.92 | +3.3% | 31 Jul 2025 | 5 Nov 2025 |
| Finance costs | Quarter to Jun 2025 | Standalone | 223.29 | 238.42 | +6.8% | 31 Jul 2025 | 5 Nov 2025 |
| Depreciation and amortisation | Quarter to Jun 2025 | Standalone | 299.03 | 310.92 | +4.0% | 31 Jul 2025 | 5 Nov 2025 |
| Other expenses | Quarter to Jun 2025 | Standalone | 1,504.40 | 1,527.23 | +1.5% | 31 Jul 2025 | 5 Nov 2025 |
| Total expenses | Quarter to Jun 2025 | Standalone | 4,233.13 | 4,234.69 | 0.0% | 31 Jul 2025 | 5 Nov 2025 |
| Profit before tax | Quarter to Jun 2025 | Standalone | 1,184.88 | 1,176.26 | −0.7% | 31 Jul 2025 | 5 Nov 2025 |
| Tax | Quarter to Jun 2025 | Standalone | 431.35 | 431.20 | 0.0% | 31 Jul 2025 | 5 Nov 2025 |